---
schema_version: "secwatch.filing_event.v1"
accession: "0001321732-23-000126"
form_type: "8-K"
ticker: "PEN"
cik: "0001321732"
company_name: "Penumbra Inc"
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:32:29.672378+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Penumbra Q3 revenue $270.9M (+26.8% YoY); raises full-year revenue guidance to $1.05B-$1.07B

## Summary
- Revenue $270.9M (+26.8% YoY, +25.9% constant currency); thrombectomy products revenue $179.1M (+38.0% YoY).
- Income from operations $12.6M; non-GAAP income from operations $33.2M. Net income $9.2M; adjusted EBITDA $51.5M (19.0% margin).
- Gross margin improved to 65.6% from 63.3% YoY, driven by favorable product mix and higher volume.
- Recorded $18.2M one-time expense for acquired IPR&D; total operating expenses 60.9% of revenue.
- Q4 2023 revenue growth expected 28%-31% YoY; full year 2023 revenue guidance raised to $1.05B-$1.07B.

## SEC filing metadata
- accession: 0001321732-23-000126
- form_type: 8-K
- ticker: PEN
- cik: 0001321732
- company_name: Penumbra Inc
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321732/000132173223000126/0001321732-23-000126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321732/000132173223000126/pen-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001321732-23-000126
- JSON: https://secwatch.observer/filing/0001321732-23-000126.json
- Plain text: https://secwatch.observer/filing/0001321732-23-000126.txt

## Key facts
- Earnings Releases
  Penumbra Inc reported the third quarter ended September 30, 2023 results: revenue $270.9 million, net income $9.2 million.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $270.9 million
  - Net income: $9.2 million
  - Result: reported results
  source text: Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2023. • Revenue of $270.9 million in the third quarter of 2023, an increase of 26.8% or 25.9% in constant currency 1 , compared to the third quarter of 2022. • Revenue of $179.1 million from sales of our
  evidence_url: https://www.sec.gov/Archives/edgar/data/1321732/000132173223000126/0001321732-23-000126-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.